Why the study?
Do plasma levels of beta-thromboglobulin and platelet factor 4 correlate with cancer disease stage and change with intravenous chemotherapy?
Do plasma levels of beta-thromboglobulin and platelet factor 4 correlate with cancer disease stage and change with intravenous chemotherapy?
Patients with clinically active cancer exhibit elevated levels of beta-thromboglobulin, suggesting ongoing in vivo platelet activation that may contribute to increased thromboembolism risk, which is not immediately altered by intravenous chemotherapy.
Answers are grounded in this paper and cite their sources.
Elevated beta-thromboglobulin in active cancer may indicate platelet activation contributing to thromboembolism risk unaffected immediately by chemotherapy; hypothesis-generating for targeted interventions.
Plasma level of beta-thromboglobulin (BTG) and platelet factor 4 (PF4), two platelet-specific proteins, were measured in 20 patients with cancer. None of the patients had evidence of thromboembolism or impaired renal function, and none was taking drugs known to interfere with platelet function. In ten patients who were in complete remission or whose disease was thought to be inactive, the levels of both proteins were essentially within normal limits. The other ten patients had active or progressive symptomatic disease. BTG level was elevated in all but one patient, and PF4 was raised in two patients. These results suggest that in patients with clinically active cancer, a state of ongoing in vivo platelet activation may be present, a phenomenon which may contribute to the known increased occurrence of thromboembolism in patients with malignancy. The intravenous administration of various cytotoxic drugs used in cancer chemotherapy produced no immediate measurable changes in BTG and PF4 level.
No takes yet. Share an insight, caveat, or question.
Hamid Al‐Mondhiry (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: